PRISM Overview

  • Founded
  • 2006

Founded

  • Status
  • Private

  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $11.8M

  • Investors
  • 9

PRISM General Information

Description

Developer of therapeutic treatment designed to provide non-oncology indications. The company develops therapeutic agents that are used to cure pulmonary fibrosis, cancer, and incurable diseases, enabling medical practitioners to help people to cure their diseases.

Contact Information

Website
www.prismbiolab.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 2-26-1 Muraoka-Higashi
  • Kanagawa Prefecture Shonan Eye Park
  • Fujisawa, 251-8555
  • Japan
+81 0000-00-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

PRISM Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series C) 09-Sep-2021 $11.8M 000.00 Completed Generating Revenue
3. Later Stage VC (Series C) 13-Jun-2013 000.00 000.00 000.00 Completed Generating Revenue
2. Later Stage VC (Series B) 03-Jun-2011 $6.16M $17M 0000 Completed Startup
1. Early Stage VC (Series A) 26-Nov-2010 $10.8M $10.8M 000.00 Completed Startup
To view PRISM’s complete valuation and funding history, request access »

PRISM Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Class C Preferred 0,000 00000.00 00000.00 00 00000.00 00.000
Class B Preferred 0,000 00000.00 00000.00 00 00000.00 00.000
Class A Preferred 4,455 $1992.48 $1992.48 1x $1992.48 26.88%
To view PRISM’s complete cap table history, request access »

PRISM Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of therapeutic treatment designed to provide non-oncology indications. The company develops therapeutic agents
Drug Discovery
Fujisawa, Japan
000.00
00000000000 000.00

000000

sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labo
0000000000000
Plymouth Meeting, PA
000 As of 0000
000.00
00000000 000.00

000000

lit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim
0000000000000
Monmouth Junction, NJ
00 As of 0000
00000
00000000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

PRISM Competitors (7)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA 000 000.00 00000000 000.00
0000000 Corporation Monmouth Junction, NJ 00 00000 00000000
00000 & 00. Corporation Rahway, NJ 00000 000.00 000000000 000.00
0000000-00000 0000 Corporation New York, NY 00000 000.00 000000000 00 000.00
00000000 000000000 Corporation Melbourne, Australia 00 00000000
You’re viewing 5 of 7 competitors. Get the full list »

PRISM Patents

  • 162

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 7

    Granted

  • 5

    Pending

  • 000

    Expiring in next 12 mo

PRISM Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4225760-A1 Novel bicyclic compounds Pending 10-Oct-2020 0000000000
US-20230265104-A1 Novel heterocyclic compounds Pending 16-Jul-2020 0000000000
EP-4182317-A1 Novel heterocyclic compounds Pending 16-Jul-2020 0000000000
JP-2023535847-A Novel heterocyclic compound Pending 16-Jul-2020 0000000000
JP-WO2020122022-A1 Liver function improving agent Pending 10-Dec-2018
To view PRISM’s complete patent history, request access »

PRISM Executive Team (6)

Name Title Board Seat Contact Info
Dai Takehara President & Co-Chief Executive Officer
Hiroyuki Kouji Ph.D Founder & Co-Chief Executive Officer
Tetsushi Inada Ph.D President
Michihiro Maeda CFO & Director Administrative Department
Tatsuya Toma Ph.D CTO & Research and Development Department
You’re viewing 5 of 6 executive team members. Get the full list »

PRISM Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
DCI Partners Venture Capital Minority 000 0000 000000 0
Eisai Innovation Corporate Venture Capital Minority 000 0000 000000 0
Gemseki Corporation Minority 000 0000 000000 0
Healthcare Innovation Venture Capital Minority 000 0000 000000 0
Newton BioCapital Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »

Ready to get started?

Request a free trial